AZTR

0.51682.75%
TM

Travis M. Whitfill

Co-Founder, COO, Secretary & Director

Dr. Travis M. Whitfill, M.P.H, MPhil, Ph.D., had been an Independent Director at IN8bio, Inc. since May 2018 until May 9, 2025. Dr. Whitfill has served as a Partner at Bios Equity Partners, LP, a biotechnology-focused venture capital firm, since October 2015 and a Senior Analyst at Bios Research since September 2014. He had served in various roles at Azitra Inc. including Chief Scientific Officer from January 2014 to September 2019. Dr. Whitfill also served as an Executive Director of Advanced Technology and Chairman of Scientific Advisory Board at Azitra Inc since August 27, 2019. He is Co-Founder and Director of Azitra Inc. and also serves as its Chief Operating Officer since June2023 and served as its Treasurer. He serves as Secretary of Azitra Inc. He was Associate Research Scientist in the Department of Pediatrics at Yale University from July 2016 to March 2022, with appointments in the Departments of Pediatrics and Emergency Medicine. Dr. Whitfill has led numerous grant-funded projects, holds several patents and has co-authored over 50 publications. Dr. Whitfill serves as a Director of Incysus Therapeutics, Inc. He was a Director of 410 Medical Inc. from September 2017 to July 2019. Dr. Whitfill has served on the board of directors of SIRPant Immunotherapeutics since September 2021. He received scientific training at various academic institutions, including M.D. Anderson Cancer Center, Duke University and Yale University. He obtained a Master of Public Health from Yale University in 2014 with an emphasis on molecular epidemiology. Dr. Whitfill received a B.S. from Dallas Baptist University and a MPhil from UCL in the United Kingdom. Dr. Whitfill has Ph.D. in Health Policy from University College London. Dr. Whitfill has M.Phil. from University College London.

Positions